Glenmark Pharmaceuticals expands its OTC portfolio

Acquires four approved ANDAs from Wockhardt

Glenmark Pharmaceuticals announced that its fully owned subsidiary Glenmark Pharmaceuticals Inc., USA (Glenmark) has acquired the approved Abbreviated New Drug Applications (ANDAs) for Famotidine Tablets USP, 10 mg and 20 mg (OTC), Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg (OTC), Lansoprazole DelayedRelease Capsules USP, 15 mg (OTC) and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) in the United States from Wockhardt.

Powered by Capital Market - Live News